pharmaceutical ingredient (API) was dissolving at rates 20% lower than those documented during lab-scale trials.

Inconsistent Values: Multiple batches exhibited inconsistency in the dissolution results, complicating the assessment of batch-to-batch variability.

Visual Inspection: Tablets showed irregularities including cracks and color inconsistencies, suggesting possible formulation issues.

These symptoms highlighted a potential risk to product quality and necessitated immediate action to investigate and address the underlying issues.

Likely Causes

Understanding the potential causes of dissolution drift requires analyzing various categories. Below are the likely causes identified:

Category	Potential Cause
Materials	Variability in raw materials or changed suppliers affecting quality.
Method	Altered dissolution methodology between lab and pilot scale.
Machine	Differences in equipment calibration and maintenance protocols.
Man	Variability in operator technique or training deficits in handling equipment.
Measurement	Differences in analytical instrumentation leading to compromised results.
Environment	Inconsistent environmental conditions (temperature, humidity) affecting batch stability.

Identifying specific causes is crucial for developing effective containment and corrective strategies.

Immediate Containment Actions (first 60 minutes)

Upon identifying the symptoms, containment actions must be immediate and thorough to prevent compromised batches from reaching later production stages. The following steps were taken:

• Isolate Affected Batches: Batches demonstrating dissolution drift were immediately segregated to prevent further testing.
• Document Observations: Detailed records of the conditions and settings during the testing were logged, including dissolution apparatus setup and any observed deviations.
• Stop Further Testing: Any ongoing dissolution testing was halted to preserve current data integrity.
• Notify Stakeholders: Relevant team members from Quality Control (QC), Quality Assurance (QA), and Manufacturing were informed to coordinate a response to the issue.

These immediate actions minimized the risk of widespread failure while preparing for an in-depth investigation.

Investigation Workflow (data to collect + how to interpret)

Effective investigations rely on a structured approach to gather and analyze data. The workflow initiated in this case study consisted of the following key steps:

• Data Compilation: Assemble all relevant data associated with the batches, including raw material sources, equipment calibration logs, operator training records, and previous dissolution results.
• Interviewing Personnel: Conduct interviews with operators and scientists involved in both lab and pilot scale stages to gather insights into procedural variances and issues faced during production.
• Pareto Analysis: Utilize Pareto analysis to prioritize issues based on frequency and impact, allowing the team to focus first on the most likely root causes.

This data-driven approach allowed the investigation team to interpret trends over time and correlate them with specific procedural variations. Analysis of previous dissolution profiles also helped establish a baseline for comparison.

Root Cause Tools (5-Why, Fishbone, Fault Tree) and when to use which

Differentiating between root cause analysis tools is crucial for developing an effective investigation strategy. Here’s how each tool can be applied in this scenario:

• 5-Why Analysis: This method helps drill down into the layers of causation by asking “why” successively. For instance, if the cause was variability in raw materials, the investigation would explore why those raw materials varied, leading to the identification of supplier inconsistencies.
• Fishbone Diagram: This visual aid structured the investigation by categorizing potential causes into the six Ms: Man, Machine, Method, Materials, Measurement, and Environment. It facilitated team brainstorming sessions, ensuring comprehensive coverage of possible issues.
• Fault Tree Analysis: Used when a more complex interplay of factors is suspected. It allowed the team to map out potential failure points and logically deduce contributing factors together.

Ultimately, choosing the right tool depends on the nature of the issue and the complexity of the contributing factors. Several tools can even be combined for a more robust investigation.

CAPA Strategy (correction, corrective action, preventive action)

The Corrective Action and Preventive Action (CAPA) process is vital for resolving issues and preventing recurrence. In this scenario, the following strategies were implemented:

• Correction: Affected batches were discarded or placed under rigorous re-analysis protocols if salvageable, ensuring out-of-spec material did not progress.
• Corrective Actions: Actions included retraining of personnel on dissolution methodologies, adjustment of calibration standards within equipment, and reverting to validated suppliers for raw materials.
• Preventive Actions: A comprehensive review of dissolution testing procedures was conducted, leading to the introduction of more stringent monitoring protocols and the establishment of enhanced supplier qualification processes.

This structured CAPA strategy helped mitigate the immediate problem while also addressing systemic issues contributing to the dissolution drift.

Related Reads

• Tech Transfer Delays and Scale-Up Failures? Practical Solutions From Lab to Commercial
• Pharmaceutical Manufacturing Scale-Up & Tech Transfer – Complete Guide

Control Strategy & Monitoring (SPC/trending, sampling, alarms, verification)

With the CAPA strategies in place, a robust control strategy was developed to proactively monitor dissolution during pilot scale production. Key elements included:

• Statistical Process Control (SPC): Implementation of SPC techniques to track dissolution fluid performance over time, utilizing data control charts to detect any significant shifts or trends.
• Enhanced Sampling: Increased frequency of sampling during the dissolution testing phases to capture variance and secure a more comprehensive dataset for analysis.
• Automated Alarms: Deployment of alarms linked to dissolution apparatus for immediate notification of deviations from set thresholds in real time.
• Verification Steps: Integration of regular reviews of dissolution data and trends into monthly quality review meetings to ensure continued compliance with established specifications.

This proactive approach solidified confidence in the dissolution process and helped validate the consistency of product quality transitioning from lab to pilot scale.

Validation / Re-qualification / Change Control impact (when needed)

The incident stressed the importance of validation and change control in pharmaceutical processes. As a result of the findings from the investigation:

• Validation Re-assessment: A thorough reassessment of the dissolution methodology was mandated, involving a re-validation of equipment and dissolution techniques under pilot scale conditions.
• Change Control Measures: Any modifications to materials or processes were subjected to strict change controls to ensure their impact on dissolution characteristics were fully evaluated.
• Procedure Documentation Updates: Standard Operating Procedures (SOPs) governing dissolution testing were revised based on the outcomes of the investigation and updated procedures put in place to reinforce compliance and quality.

Validation of new processes and equipment is crucial for maintaining product integrity, emphasizing the need for a systematic approach to change control.

Inspection Readiness: what evidence to show (records, logs, batch docs, deviations)

To ensure inspection readiness post-incident, specific documentation was emphasized:

• Batch Records: Complete and meticulous records for affected batches, including dissolution testing protocols, conditions, results, and deviations.
• Investigation Reports: Detailed records of the investigation outcomes, including root cause analyses, CAPA documentation, and any subsequent actions taken.
• Training Logs: Documentation confirming retraining of personnel in line with new protocols ensures that the knowledge within the organization is current and effective.
• Monitoring Records: SPC charts, alarm logs, and sampling reports illustrating the effectiveness of new controls instituted after the incident.

Maintaining robust documentation not only ensures compliance but also demonstrates a proactive commitment to quality and improvement to inspectors from regulatory agencies.

FAQs

What is dissolution drift?

Dissolution drift refers to the unexpected variance in dissolution rates observed when transitioning from lab-scale to pilot-scale production.

How can I identify early symptoms of dissolution drift?

Symptoms such as differing dissolution rates compared to lab-scale tests, visual irregularities in product appearance, and batch inconsistency are early indicators of possible issues.

What immediate actions should I take upon detecting dissolution drift?

Isolate affected batches, document observations, stop further testing, and notify key stakeholders to initiate a coordinated response.

Which root cause analysis tool is best for my investigation?

The choice of tool depends on complexity; 5-Why is good for straightforward issues, Fishbone for categorical brainstorming, and Fault Tree for complex interdependencies.

How often should I monitor dissolution rates in pilot-scale production?

Monitoring should be frequent enough to capture significant trends, typically aligned with SPC guidelines for effective data analysis.

What records are important for inspection readiness?

Essential records include batch records, investigation reports, training logs, and monitoring documentation illustrating compliance and corrective actions.

How can I improve my CAPA process?

Ensure your CAPA process includes clearly defined steps for correction, corrective action, and preventive action with ongoing review and adjustments as needed.

What regulatory bodies should I follow for guidance on dissolution testing?

Guidance can be found through official sources such as the FDA, EMA, and MHRA.